Download PDF
PSYCH up2date 2016; 10(01): 47-64
DOI: 10.1055/s-0041-106154
Essstörungen, somatische Belastungsstörungen, Schlafstörungen und sexuelle Funktionsstörungen

Medikamentöse Behandlung der Adipositas

Stefan Engeli
› Further Information
Also available at
    Permissions and Reprints All articles of this category
Kernaussagen

  • In begründeten Fällen ist eine medikamentöse Unterstützung der Gewichtsreduktion gerechtfertigt. Die Leitlinien der Deutschen Adipositas-Gesellschaft geben hierfür den Rahmen vor.

  • Durchschnittlich kann zusätzlich zu einem Basisprogramm mit Lebensstilmodifikationen eine Gewichtsreduktion von etwa 3 – 7 kg durch adjuvante medikamentöse Therapie erzielt werden.

  • Aktuell ist in Deutschland nur ein Medikament mit Wirksamkeitsnachweis verfügbar: der Lipasehemmer Orlistat.

  • Andere verschreibungspflichtige oder apothekenpflichtige Medikamente ohne Wirksamkeitsnachweis sollten nicht verordnet werden.

  • Die Markteinführung der in Europa in diesem Jahr für die Gewichtsreduktion zugelassenen Liraglutid und Naltrexon/Bupropion lässt auf sich warten.

  • Besonders zu beachten sind stets kardiovaskuläre und psychische unerwünschte Wirkungen sowie Arzneimittelinteraktionen.

  • Vom Off-Label-Einsatz von Medikamenten mit gewichtsreduzierender Wirkung als Nebeneffekt ist dringend abzuraten.



Publication History

Publication Date:
14 January 2016 (online)

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 AWMF. Interdisziplinäre Leitlinie der Qualität S3 zur „Prävention und Therapie der Adipositas“. Im Internet: Accessed October 22, 2015 at: http://www.awmf.org/leitlinien/detail/ll/050-001.html
  • 2 May M, Engeli S. Pharmakokinetische Besonderheiten bei adipösen Patienten. Adipositas 2014; 8: 89-94
    Search in Google Scholar
  • 3 Chobanyan-Jürgens K, May M. Besonderheiten der Antikoagulation bei adipösen Patienten. Adipositas 2015; 9: 64-72
    Search in Google Scholar
  • 4 Merlotti C, Morabito A, Ceriani V. et al. Prevention of type 2 diabetes in obese at-risk subjects: a systematic review and meta-analysis. Acta Diabetol 2014; 51: 853-863
    CrossrefPubMedSearch in Google Scholar
  • 5 Siebenhofer A, Jeitler K, Berghold A. et al. Long-term effects of weight-reducing diets in hypertensive patients. Cochrane Database Syst Rev. 2011; 9: CD008274
    Search in Google Scholar
  • 6 Jumpertz R, Le DS, Turnbaugh PJ. et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011; 94: 58-65
    CrossrefPubMedSearch in Google Scholar
  • 7 Reinhardt M, Thearle MS, Ibrahim M. et al. A human thrifty phenotype associated with less weight loss during caloric restriction. Diabetes 2015; 64: 2859-2867
    CrossrefPubMedSearch in Google Scholar
  • 8 Middleton KM, Patidar SM, Perri MG. The impact of extended care on the long-term maintenance of weight loss: a systematic review and meta-analysis. Obes Rev 2012; 13: 509-517
    CrossrefPubMedSearch in Google Scholar
  • 9 Sjöström L, Peltonen M, Jacobson P. et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. J Am Med Assoc 2014; 311: 2297-2304
    CrossrefPubMedSearch in Google Scholar
  • 10 de Zwaan M, Enderle J, Wagner S. et al. Anxiety and depression in bariatric surgery patients: a prospective, follow-up study using structured clinical interviews. J Affect Disord 2011; 133: 61-68
    CrossrefPubMedSearch in Google Scholar
  • 11 Toplak H, Woodward E, Yumuk V. et al. 2014 EASO Position Statement on the Use of Anti-Obesity Drugs. Obes Facts 2015; 8: 166-174
    CrossrefPubMedSearch in Google Scholar
  • 12 Jones BJ, Bloom SR. The new era of drug therapy for obesity: the evidence and the expectations. Drugs 2015; 75: 935-945
    CrossrefPubMedSearch in Google Scholar
  • 13 Burke LK, Heisler LK. 5-hydroxytryptamine medications for the treatment of obesity. J Neuroendocrinol 2015; 27: 389-398
    CrossrefPubMedSearch in Google Scholar
  • 14 Caterson ID, Finer N, Coutinho W. et al. SCOUT Investigators. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012; 14: 523-530
    CrossrefPubMedSearch in Google Scholar
  • 15 Engeli S. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol 2012; 209: 357-381
    CrossrefPubMedSearch in Google Scholar
  • 16 Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004; 80: 1461-1468
    CrossrefPubMedSearch in Google Scholar
  • 17 Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002; 20: 1873-1878
    CrossrefPubMedSearch in Google Scholar
  • 18 Torgerson JS, Hauptman J, Boldrin MN. et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161
    CrossrefPubMedSearch in Google Scholar
  • 19 Fachinformation Xenical® 120 mg Hartkapseln (Juni 2014).
  • 20 Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470-512
    CrossrefPubMedSearch in Google Scholar
  • 21 Engeli S, Jordan J. Blood pressure effects of glucagon-like peptide 1 analogues and sodium glucose transporter 2 inhibitors. Curr Opin Nephrol Hypertens 2014; 23: 468-472
    CrossrefPubMedSearch in Google Scholar
  • 22 Astrup A, Carraro R, Finer N. et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes 2012; 36: 843-854
    CrossrefPubMedSearch in Google Scholar
  • 23 European Medicines Agency. Investigation into GLP-1-based diabetes therapies concluded. Im Internet: Accessed October 22, 2015 at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001856.jsp&mid=WC0b01ac058004d5c1
  • 24 Pi-Sunyer X, Astrup A, Fujioka K. et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22
    CrossrefPubMedSearch in Google Scholar
  • 25 Davies MJ, Bergenstal R, Bode B. et al. NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. J Am Med Assoc 2015; 314: 687-699
    CrossrefPubMedSearch in Google Scholar
  • 26 Fachinformation Victoza® 6 mg/ml Injektionslösung (März 2015).
  • 27 Katsiki N, Hatzitolios AI, Mikhailidis DP. Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: a new kid on the block?. Ann Med 2011; 43: 249-258
    CrossrefPubMedSearch in Google Scholar
  • 28 Greenway FL, Fujioka K, Plodkowski RA. et al. COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595-605
    CrossrefPubMedSearch in Google Scholar
  • 29 Hollander P, Gupta AK, Plodkowski R. et al. COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36: 4022-4029
    CrossrefPubMedSearch in Google Scholar
  • 30 Deutsches Ärzteblatt. Diätpille Contrave: Studienabbruch nach vorzeitigen Ergebnissen. Im Internet: Accessed October 22, 2015 at: http://www.aerzteblatt.de/nachrichten/62805/Diaetpille-Contrave-Studienabbruch-nach-vorzeitigen-Ergebnissen
  • 31 Fachinformation Elontril® 300 mg mit veränderter Wirkstofffreisetzung (Dezember 2014).
  • 32 Fachinformation Adepend® 50 mg (Oktober 2012).
  • 33 Jordan J, Astrup A, Engeli S. et al. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens 2014; 32: 1178-1188
    CrossrefPubMedSearch in Google Scholar
  • 34 Fachinformation Topamax® 100 mg Filmtabletten (Oktober 2014).
  • 35 European Medicines Agency. Refusal of the marketing authorisation for Qsiva. Im Internet: Accessed October 22, 2015 at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002350/WC500139215.pdf
  • 36 Gadde KM, Allison DB, Ryan DH. et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-1352
    CrossrefPubMedSearch in Google Scholar
  • 37 Garvey WT, Ryan DH, Look M. et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95: 297-308
    CrossrefPubMedSearch in Google Scholar
  • 38 Garvey WT, Ryan DH, Bohannon NJ. et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care 2014; 37: 3309-3316
    CrossrefPubMedSearch in Google Scholar
  • 39 Federal Register. Schedules of Controlled Substances: Placement of Lorcaserin Into Schedule IV. Im Internet: Accessed October 22, 2015 at: https://www.federalregister.gov/articles/2012/12/19/2012-30531/schedules-of-controlled-substances-placement-of-lorcaserin-into-schedule-iv
  • 40 Smith SR, Weissman NJ, Anderson CM. et al. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245-256
    CrossrefPubMedSearch in Google Scholar
  • 41 Fidler MC, Sanchez M, Raether B. et al. BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96: 3067-3077
    CrossrefPubMedSearch in Google Scholar
  • 42 O'Neil PM, Smith SR, Weissman NJ. et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 2012; 20: 1426-1436
    CrossrefPubMedSearch in Google Scholar
  • 43 Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. J Am Med Assoc 2014; 311: 74-86
    CrossrefPubMedSearch in Google Scholar